ETFs Immatics N.V.

IMTX

NL0015285941

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-03 EDT			5-day change	1st Jan Change
9.460 ^USD	-0.42%		+1.07%	-9.90%

08-25	Immatics Announces $150 Million Underwritten Offering	MT
08-18	Immatics' Q2 Net Loss Narrows as Revenue Rises	MT

ETFs positioned on Immatics N.V.

Name	YTD change	Weight	AuM
STATE STREET SPDR PORTFOLIO DEVELOPED WORLD EX-US ETF - USD	+17.32%	-.--%	41,780 M€
VIRTUS LIFESCI BIOTECH CLINICAL TRIALS ETF - USD	+38.46%	0.76%	50 M€
STATE STREET SPDR S&P KENSHO NEW ECONOMIES COMPOSITE ETF - DISTRIBUTING - USD	+13.01%	0.09%	2,826 M€
STATE STREET SPDR S&P INTERNATIONAL SMALL CAP ETF - USD	+14.32%	0.06%	918 M€
INNOVATOR U.S. SMALL CAP MANAGED FLOOR ETF - USD	+14.81%	0.05%	94 M€
STATE STREET SPDR GLOBAL ALLOCATION ETF - DISTRIBUTING - USD	+9.30%	0%	317 M€
DEFINED DURATION 20 ETF - USD	+15.02%	0%	19 M€
DISCIPLINE FUND ETF - USD	-.--%	0%	73 M€
DEFINED DURATION 5 ETF - USD	+1.80%	0%	18 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+15.70%	0%	62 M€
CAMBRIA US EW ETF - USD	+12.13%	0%	194 M€

Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Modernaâ€™s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.

Employees

704

Sector

Biotechnology & Medical Research

More about the company